Specifications
Immunogen
Recombinant protein corresponding to human SNCA.
Applications
Application Notes
ELISA (1:10000); WB (1:500-1:2000); Immunohistochemistry (1:200-1:1000) & The optimal working dilution should be determined by the end user.
Target
Alternative Names
SNCA; synuclein, alpha (non A4 component of amyloid precursor); PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4; alpha-synuclein; alpha synuclein; NACP; PD1; synuclein alpha-140; non A-beta component of AD amyloid; PARK1; PARK4; MGC11098
Product Background
Antigen Description
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimers disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.
Pathway
Alpha-synuclein signaling, organism-specific biosystem; Alzheimers disease, organism-specific biosystem; Alzheimers disease, conserved biosystem; Amyloids, organism-specific biosystem; Disease, organism-specific biosystem; EGFR1 Signaling Pathway, organism-specific biosystem; Parkinsons disease, organism-specific biosystem;
Citations
Publication ()
Have you cited DCABH-13532 in a publication?
Let us know and earn a reward for your research.